Best Ophthalmology podcasts — Eye and vision research (Updated October 2017; image)
Related podcasts: Science Retina Cataract Medicine Health and Well-Being Glaucoma Cornea Business Eyes Optometry Spine Medical Brain Health Tech Education US Government Duke Health Diabetes And Endocrinology Cme/ce  
public [subscription 1120]
show episodes
 
M
Medscape Ophthalmology Podcast
Monthly
 
Latest medical news and features from Medscape Ophthalmology
 
A
As Seen From Here
Monthly+
 
the Ophthalmology podcast
 
O
OIS Podcast
Weekly
 
Welcome to the Ophthalmology Innovation Podcast where you get candid conversations with the leaders & drivers of ophthalmic innovation.
 
Loading …
show series
 
Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an eye toward developing specific treatments for patients with connected genetic codes. CEO, president, and co-founder James McLaughlin explains how Gemin ...…
 
Guests: Marcony Santhiago, MD, PhD Professor of Ophthalmology Federal University of Rio de Janeiro and the University of Sao Paulo, Brazil Warren Hill, MD East Valley Ophthalmology Mesa, AZ
 
CEO Paul Chaney details the company’s plans to move forward with $11 million in new capital. He also recounts how his unplanned entry into ophthalmology led him to appreciate how special the specialty truly is. Chaney also explains why PanOptica’s pursuit of an eye-drop-based treatment for AMD and DR is personal.…
 
With $3 million to invest in first-time funds, impact investor ExSight Capital built a promising and productive portfolio that included gene therapy company RetroSense. Now, ExSight co-founder and partner Firas M. Rahhal, MD, says the firm is planning to raise a much larger fund that could elevate its standing as a seed-stage investor in ophtha ...…
 
Guest: Chris Rudnisky, MD, MPH Professor, Department of Ophthalmology University of Alberta Edmonton, Alberta Canada
 
Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as combination therapies and other products push through late-stage clinical trials. What technologies show the most promise? What advances have surprise ...…
 
Christy Shaffer, PhD, general partner at Hatteras Venture Partners, didn’t have a career map that led her into the corner office at Inspire Pharmaceuticals or into the partnership at Hatteras Venture Partners. But the clinical scientist grew to succeed in both roles. Dr. Shaffer led Inspire when the company conceived and then built out its opht ...…
 
Guests: Gerd Auffarth, MD Chairman, Dept. of Ophthalmology University of Heidelberg Heidelberg, Germany Robert Edward T. Ang, MD Asian Eye Institute Makati City, Philippines
 
Accomplished ophthalmologist Mark Blumenkranz, MD, moved early into the Digital Health space by co-founding Digisight, one of the more advanced efforts in ophthalmology. Six years, later, Dr. Blumenkranz still sees enormous opportunity so he’s working with the FDA and top clinical societies to hold a one-day workshop for physicians, investors, ...…
 
In 2011, Cal Roberts, MD, got an unexpected call from Brent Saunders, then head of Bausch & Lomb. Saunders asked if Dr. Roberts would trade a thriving ophthalmology practice to serve as chief medical officer at the eye care giant. Today, Dr. Roberts is thrilled with the decision, and other ophthalmology companies are following the example, brin ...…
 
A
As Seen From Here
 
Guest: Sung Chul (Sean) Park, MD Assistant Professor of Ophthalmology Director, Glaucoma Clinic and Research Manhattan Eye, Ear and Throat Hospital Hofstra Northwell School of Medicine New York, NY
 
Even moderate improvements in hyperglycemia, hypertension, and hyperlipidemia can yield substantial results.
 
M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, shares details of the institute’s detection of apoptosing retinal cells (DARC) scan – which employs a new retinal biomarker. The DARC system, which will undergo further trials, could allow for earlier detection of retinal disease in patients ...…
 
Charles Semba, MD, is one of the more recognized and accomplished figures in development of new ophthalmology treatments. He has played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer at Graybug Vision, Dr. Semba is working to develop a technology tha ...…
 
Dr Christopher Rapuano discusses the likely outcomes and recovery for this newly approved treatment for keratoconus.
 
Guests: Soon Phaik Chee, MD Associate Professor Singapore National Eye Centre Singapore Mingguang He, MD, PhD Professor of Ophthalmic Epidemiology University of Melbourne and Centre for Eye Research Australia Director of WHO Collaborating Centre for Prevention of Blindness (Australia) Melbourne, Australia…
 
OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the second OIS@ASRS. Dr. Humayun, the outgoing ASRS president, shares details on his next undertaking – finding a way to measure the value of vision protection. Meanwhile, Dr. Pollack highlights one of his ...…
 
OIS Co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, managing director, Clarus Funds, walks us through the agenda of Thursday’s OIS@ASRS. What areas of retina will dominate the headlines for the next 12 months?
 
Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the globa ...…
 
Dr Christopher Rapuano sorts through the updated recommendations for dry eye provided in the recently published report of the Tear Film & Ocular Surface Society International Dry Eye Workshop II.
 
Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?…
 
Guest: Laura M. Periman, MD Seattle, WA
 
Join in as two ophthalmologists have an in-depth discussion about vancomycin-associated hemorrhagic occlusive retinal vasculitis, including its diagnosis, treatment, and prognosis.
 
In two recent interviews, Elizabeth Yeu, MD, Virginia Eye Consultants, and Richard Lewis, MD, Sacramento Eye Consultants share how innovation is changing how they treat patients. Reimbursement, marketing and the future of new tech also are discussed.
 
In this OIS Podcast, David Alpern, partner at Varsity Healthcare Partners, and Brent Wilde, president of Minnesota Eye Consultants, offer complimentary perspectives on Private Equity’s impact on ophthalmology practices.
 
Guest: Laura M. Periman, MD Seattle, WA
 
Jerry St. Peter, VP & head, ophthalmic business, says the ophthalmology newcomer is making great progress in building a broad pipeline to treat eye disease including dry eye and ocular pain. In this interview he reviews several acquisitions and partnerships the company has made over the past 24 months.…
 
Laurent Attias, head, strategy, BD&L and M&A, reports on progress on Alcon’s project with Google and its advancing glaucoma portfolio. Attias says Alcon is “open for business” and continuing to advance innovative ideas in ophthalmology.
 
Guests: Boris Malyugin, MD, PhD Professor of Ophthalmology Department of Cataract & Implant Surgery Deputy Director General S.Fyodorov Eye Microsurgery State Institution Moscow, Russia Adi Abulafia, MD Acting Deputy Head of Ophthalmology Department Assaf HaRofeh Medical Center Tzrifin, Israe
 
After capturing lighting in a bottle with Oculeve, Ali Behbahani, MD, partner of New Enterprise Associates, recalls the experience with the Dry Eye start-up and lays out his plans for investing in future ophthalmology start-ups.
 
Max G. Ostermeier, MBA, co-founder and general manager of Implandata Ophthalmic Products GmbH, charts a course for the company after securing CE mark for its EYEMATE eye pressure measurement system for continuous measurement of IOL in patients with glaucoma.
 
Physicians from all over the country tell Medscape about their experiences with the ACA. What's your take?
 
Guest: Priya Narang, MS Narang Eye Care & Laser Centre Ahmedabad, India
 
Mynosys Cellular Devices CEO and president John Hendrick lays out his company’s plan to roll out Zepto in the US. The firm has reported strong demand in OUS markets, and Hendrick anticipates it will upend the capsulotomy market.
 
Eric Donnenfeld, MD, founding partner of OCLI, shares how his practice is incorporating new diagnostics and treatments. “I spend less time diagnosing the disease and it enables me to spend more time talking to the patients about therapies,” Dr. Donnenfeld says. He also praises Shire and Allergan for their effective marketing.…
 
Guests: Arsham Sheybani, MD Assistant Professor Ophthalmology and Visual Sciences Washington University School of Medicine St Louis, MO Devesh Varma, MD Assistant Professor Department of Ophthalmology & Vision Sciences University of Toronto School of Medicine Toronto, ON, Canada
 
In this interview, Tom Mitro, COO of Aerie Pharmaceuticals, says new hires brought on to prepare for likely commercial sale of Rhopressa bring new life and energy into a company hitting its stride. He also provides to OIS@ASCRS an update on the firm’s glaucoma pipeline.
 
Ludwin Monz, PhD, President and CEO of Carl Zeiss Meditec explains why the ophthalmology leader brought in new senior leadership. He also reviews the company’s recent product approvals and gives an assessment of the “amazing possibilities” within diagnostics.
 
Now that Shire’s Xiidra claims a 20% market share, find out how it’s impacting the practice. Alice Epitropoulos, MD, of Ophthalmic Surgeons & Consultants of Ohio, sat down with OIS-TV to explain how Shire, TrueTear, and other advances are impacting her Dry Eye patients.
 
Guest: Greg Moloney, MD Mosman, Australia
 
LensGen CEO Ram Rao discusses his company’s $21 million Series A and the increased interest in presbyopia.
 
Guests: Ehud Assia, MD Professor of Ophthalmology Tel-Aviv University Medical School Tel-Aviv, Israel Jeffrey Whitman, MD   Dallas, TX
 
Emmett Cunningham, MD, Gil Kliman, MD, and Bill Link, PhD, co-chairs of OIS, talk about device funding, myopia, and the Masters of the Industry following a successful OIS@ASCRS.
 
Gil Kliman, managing director at InterWest Partners, reviews his role at the upcoming OIS@ASCRS, including an overview of anterior segment innovation and a discussion on lower myopia.
 
Longtime eye bank executive David Korroch, chief executive officer, Lions Medical Eye Bank, explains how eye banks have worked hard to meet – and even exceed – the demand for donated tissue. Korroch is the winner of this year’s Leonard Heise Award.
 
A
As Seen From Here
 
Guest: Jodhbir Mehta, MD Associate Professor, Head of Cornea External Disease, Senior Consultant in Refractive Surgery Singapore National Eye Centre Singapore
 
Mark S. Blumenkranz, MD, H. J. Smead Professor of Ophthalmology, Emeritus, delivers his State of Innovation address. You can guess what his assessment is, but we’ll give you a hint. It involves cool lasers.
 
Guests: Garry Condon, M.D. Pittsburgh, PA Robert J. Cionni, M.D. Salt Lake City, UT
 
OIS Co-Chair William J. Link, PhD walks us through OIS@ASCRS’ May 4 agenda, which takes place in LA. Link also explains why he Andy Corley and Richard Lindstrom, MD, formed Flying L Partners. Hear about the firm’s most recent investment.
 
Speed
Series preference
1x
1x
Volume
100%
/

Google login Twitter login Classic login